ABSTRACT
Background
Spontaneous Adverse Event Reporting (SAER) databases play a crucial role in post-marketing drug surveillance. However, the traditional model-free disproportionality analysis has been challenged by the insufficiency in investigating subgroup and confounders. These issues result in significant low-precision and biases in data mining for SAER.
Methods
The Model-Driven Reporting Odds Ratio (MD-ROR) was proposed to bridge the gap between SAER database and explainable models for exploring individual and confounding effects. MD-ROR is grounded in a well-designed model, rather than a 2 × 2cross table, for estimating AE-drug signals. Consequently, individual and confounding effects can be parameterized based on these models. We employed simulation data and the FDA Adverse Event Reporting System (FAERS) database.
Result
The simulated data indicated the subgroup effects estimated by MD-ROR were unbiased and efficient. Moreover, the adjusted-MD-ROR demonstrated greater robustness against confounding biases than the crude ROR. Applying our method to the FAERS database suggested higher occurrences of drug interactions and cardiac adverse events induced by Midazolam in females compared to males.
Conclusion
The study underscored that MD-ROR holds promise as a method for investigating individual and confounding effects in SAER databases.
Disclaimer
As a service to authors and researchers we are providing this version of an accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proofs will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to these versions also.Declaration of Interests
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Reviewer disclosure
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Acknowledgements
Authors thank Prof. Yueping Shen and Dr. Na Sun of the Soochow University for helpful comments about this paper.
Author Contributions
Bo Lv: Conceptualization, Methodology, Software, Data analysis, Visualization, Writing - Original Draft; Yuedong Li: Conceptualization, Validation Data Curation and Writing - Review & Editing; Aiming Shi: Supervision, Project administration, Funding acquisition; Jie Pan: Supervision, Project administration, Funding acquisition.